Search Results - "Kümmerle, T."

Predictors of serofast state after treatment for early syphilis in HIV‐infected patients by Paul, G, Wesselmann, J, Adzic, D, Malin, JJ, Suarez, I, Priesner, V, Kümmerle, T, Wyen, C, Jung, N, Bremen, K, Schlabe, S, Wasmuth, J‐C, Boesecke, C, Fätkenheuer, G, Rockstroh, J, Schwarze‐Zander, C, Lehmann, C

“…Objectives Non‐treponemal serological tests are used to monitor treatment response during syphilis infection. Syphilis‐ and HIV‐coinfected patients may…”
Get full text

To prescribe, or not to prescribe: decision making in HIV‐1 post‐exposure prophylaxis by Scholten, M, Suárez, I, Platten, M, Kümmerle, T, Jung, N, Wyen, C, Ernst, A, Horn, C, Burst, V, Suárez, V, Rybniker, J, Fätkenheuer, G, Lehmann, C

“…Objectives We investigated the trend in usage of post‐exposure prophylaxis (PEP) after HIV‐1 risk exposure and evaluated PEP prescription decision making of…”
Get full text

Echocardiographic screening for pulmonary arterial hypertension in HIV-positive patients by ten Freyhaus, H., Vogel, D., Lehmann, C., Kümmerle, T., Wyen, C., Fätkenheuer, G., Rosenkranz, S.

“…Human immunodeficiency virus (HIV) infection is associated with an increased risk for pulmonary arterial hypertension (PAH). Upon the screening of 220…”
Get full text

Causes of death in HIV-infected patients from the Cologne–Bonn cohort by Ehren, K., Hertenstein, C., Kümmerle, T., Vehreschild, J. J., Fischer, J., Gillor, D., Wyen, C., Lehmann, C., Cornely, O. A., Jung, N., Gravemann, S., Platten, M., Wasmuth, J. C., Rockstroh, J. K., Boesecke, C., Schwarze-Zander, C., Fätkenheuer, G.

“…Purpose Causes of death in human immunodeficiency virus (HIV)-infected subjects have changed in countries with high resources over the last several years…”
Get full text

P1284 : Establishment of an interdisciplinary online expert-forum (INXFO) specialized in HIV and hepatitis in Germany – up-date 2014 by Hanhoff, N, Braun, P, Ingiliz, P, Kümmerle, T, Preis, S, Rockstroh, J, Wolf, E, Wyen, C, Meemken, L

Get full text

Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in Germany by SCHWARZE-ZANDER, C., DRAENERT, R., LEHMANN, C., STECHER, M., BOESECKE, C., SAMMET, S., WASMUTH, J. C., SEYBOLD, U., GILLOR, D., WIELAND, U., KÜMMERLE, T., STRASSBURG, C. P., MANKERTZ, A., EIS-HÜBINGER, A. M., JÄGER, G., FÄTKENHEUER, G., BOGNER, J. R., ROCKSTROH, J. K., VEHRESCHILD, J. J.

“…Measles, mumps, rubella (MMR) and varicella zoster virus (VZV) infection can cause serious diseases and complications in the HIV-positive population. Due to…”
Get full text

PEPDar: A randomized prospective noninferiority study of ritonavir‐boosted darunavir for HIV post‐exposure prophylaxis by Fätkenheuer, G, Jessen, H, Stoehr, A, Jung, N, Jessen, AB, Kümmerle, T, Berger, M, Bogner, JR, Spinner, CD, Stephan, C, Degen, O, Vogelmann, R, Spornraft‐Ragaller, P, Schnaitmann, E, Jensen, B, Ulmer, A, Kittner, JM, Härter, G, Malfertheiner, P, Rockstroh, J, Knecht, G, Scholten, S, Harrer, T, Kern, WV, Salzberger, B, Schürmann, D, Ranneberg, B

“…Objectives PEPDar compared the tolerability and safety of ritonavir‐boosted darunavir (DRV/r)‐based post‐exposure prophylaxis (PEP) with the tolerability and…”
Get full text

Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic by Platten, M., Linnemann, R., Kümmerle, T., Jung, N., Wyen, C., Ehren, K., Gravemann, S., Gillor, D., Cornely, O. A., Fischer, J., Lehmann, C., Rockstroh, J. K., Fätkenheuer, G., Vehreschild, J. J.

“…Objectives Little data exist about the quality of care for HIV-infected subjects in Germany. We investigated the clinical course of HIV-infected subjects newly…”
Get full text

Liver involvement in HIV-infected patients diagnosed with syphilis by Jung, N., Kümmerle, T., Brengelmann, S. D., Gielen, J., Lehmann, C., Wyen, C., Birtel, A., Fischer, J., Gillor, D., Koch, S., Vehreschild, J. J., Cornely, O. A., Fätkenheuer, G.

“…Purpose Liver involvement in syphilis has been studied in cohorts of human immunodeficiency virus (HIV)-negative individuals despite the scarcity of data on…”
Get full text

How successful is influenza vaccination in HIV infected patients? Results from an influenza A(H1N1)pdm09 vaccine study by Schwarze-Zander, C, Steffens, B, Emmelkamp, J, Kümmerle, T, Boesecke, C, Wasmuth, J.C, Strassburg, C.P, Fätkenheuer, G, Rockstroh, J.K, Eis-Hübinger, A.M

“…Abstract Aim To determine immune response after single vaccination with AS03-adjuvanted pandemic H1N1 vaccine in HIV-infected patients. Background Individuals…”
Get full text

Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort by Steffens, B, Kümmerle, T, Koch, S, Birtel, A, Schwarze-Zander, C, Emmelkamp, J, Kern, W V, Hertenstein, C, Wyen, C, Lehmann, C, Cornely, O A, Rockstroh, J, Fätkenheuer, Gerd

“…To evaluate the acceptance and tolerability of the nH1N1 2009 vaccine in HIV-positive individuals. 758 patients were included in this prospective study…”
Get full text

Clinical and epidemiological characteristics of patients with early syphilis from three academic centres in Poland, Germany and Ireland: initial findings from the POETS study by Rowley, D, Swięcki, P, Firlag-Burkacka, E, Sabin, C, Kümmerle, T, Surah, S, Sadlier, C, O'Dea, S, Horban, A, Fätkenheuer, G, Mulcahy, F

“…Syphilis recognition in HIV-positive patients has important implications. Initial data from this study, established in June 2012 to better understand the…”
Get more information

PEPD ar: A randomized prospective noninferiority study of ritonavir‐boosted darunavir for HIV post‐exposure prophylaxis by Fätkenheuer, G, Jessen, H, Stoehr, A, Jung, N, Jessen, AB, Kümmerle, T, Berger, M, Bogner, JR, Spinner, CD, Stephan, C, Degen, O, Vogelmann, R, Spornraft‐Ragaller, P, Schnaitmann, E, Jensen, B, Ulmer, A, Kittner, JM, Härter, G, Malfertheiner, P, Rockstroh, J, Knecht, G, Scholten, S, Harrer, T, Kern, WV, Salzberger, B, Schürmann, D, Ranneberg, B

“…Objectives PEPD ar compared the tolerability and safety of ritonavir‐boosted darunavir ( DRV /r)‐based post‐exposure prophylaxis ( PEP ) with the tolerability…”
Get full text

New antiretroviral drug classes in HIV therapy by Lehmann, C, Meuer, K, Kümmerle, T, Fätkenheuer, G

Get full text

Vaccination against rabies: how and when? by Kümmerle, T, Fätkenheuer, G, Hallek, M

“…Each year, more than 55,000 people die from rabies. Rabies virus (RABV) is transmitted via bites from infected animals. Dogs represent the most important…”
Get more information

Preexposure prophylaxis for HIV infection--current data and recommendations by Kümmerle, T, Fätkenheuer, G

Get more information

Value of p53, urokinase plasminogen activator, PAI-1 and Ki-67 in vulvar carcinoma by Hoffmann, G, Casper, F, Weikel, W, Kümmerle, T, Pollow, B, Schaffrath, M, Hofmann, M, Pollow, K

“…The present study was to measure new prognostic factors including the plasminogen activator urokinase and the plasminogen inhibitor PAI-1, as well as p53 and…”
Get more information